JP2017525343A5 - - Google Patents

Download PDF

Info

Publication number
JP2017525343A5
JP2017525343A5 JP2017501280A JP2017501280A JP2017525343A5 JP 2017525343 A5 JP2017525343 A5 JP 2017525343A5 JP 2017501280 A JP2017501280 A JP 2017501280A JP 2017501280 A JP2017501280 A JP 2017501280A JP 2017525343 A5 JP2017525343 A5 JP 2017525343A5
Authority
JP
Japan
Prior art keywords
hil
antigen
binding
nmol
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017501280A
Other languages
English (en)
Japanese (ja)
Other versions
JP7209464B2 (ja
JP2017525343A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2015/055226 external-priority patent/WO2016005950A1/en
Publication of JP2017525343A publication Critical patent/JP2017525343A/ja
Publication of JP2017525343A5 publication Critical patent/JP2017525343A5/ja
Application granted granted Critical
Publication of JP7209464B2 publication Critical patent/JP7209464B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017501280A 2014-07-10 2015-07-10 ヒトインターロイキン－２に対する免疫刺激性モノクローナル抗体 Active JP7209464B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14176619.6 2014-07-10
EP14176619 2014-07-10
PCT/IB2015/055226 WO2016005950A1 (en) 2014-07-10 2015-07-10 Immune-stimulating monoclonal antibodies against human interleukin-2

Publications (3)

Publication Number Publication Date
JP2017525343A JP2017525343A (ja) 2017-09-07
JP2017525343A5 true JP2017525343A5 (cg-RX-API-DMAC7.html) 2018-08-16
JP7209464B2 JP7209464B2 (ja) 2023-01-20

Family

ID=51162588

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017501280A Active JP7209464B2 (ja) 2014-07-10 2015-07-10 ヒトインターロイキン－２に対する免疫刺激性モノクローナル抗体

Country Status (9)

Country Link
US (2) US10894828B2 (cg-RX-API-DMAC7.html)
EP (2) EP3166973B1 (cg-RX-API-DMAC7.html)
JP (1) JP7209464B2 (cg-RX-API-DMAC7.html)
CN (1) CN106604932B (cg-RX-API-DMAC7.html)
AU (1) AU2015287227B2 (cg-RX-API-DMAC7.html)
CA (1) CA2954476C (cg-RX-API-DMAC7.html)
DK (1) DK3166973T3 (cg-RX-API-DMAC7.html)
ES (2) ES2779977T3 (cg-RX-API-DMAC7.html)
WO (1) WO2016005950A1 (cg-RX-API-DMAC7.html)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL260218B2 (en) * 2016-01-11 2023-04-01 Novartis Ag Humanized monoclonal antibodies that elicit an immune response against interleukin-2, and their fusion proteins
EP3518969A2 (en) 2016-09-28 2019-08-07 Xoma (Us) Llc Antibodies that bind interleukin-2 and uses thereof
GB201621806D0 (en) * 2016-12-21 2017-02-01 Philogen Spa Immunocytokines with progressive activation mechanism
EP3585404A4 (en) * 2017-02-23 2021-04-14 City of Hope METHODS OF IN VIVO EXPANSION OF CD8 + T-LYMPHOCYTES AND PREVENTION OR TREATMENT OF GRAFT HOST REACTION (GVHD)
EA201992248A1 (ru) * 2017-03-23 2020-02-06 Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания АНТИ-C5a-АНТИТЕЛА И ИХ ПРИМЕНЕНИЯ
RU2745451C1 (ru) * 2017-05-25 2021-03-25 Инститьют Фор Бейсик Сайенс Антитела к человеческому интерлейкину-2 и их применение
CN112020510B (zh) 2018-03-19 2024-10-11 茂体外尔公司 包含用于治疗癌症的肿瘤抑制基因疗法和cd122/cd132激动剂的方法及组合物
WO2021113644A1 (en) 2019-12-05 2021-06-10 Multivir Inc. Combinations comprising a cd8+ t cell enhancer, an immune checkpoint inhibitor and radiotherapy for targeted and abscopal effects for the treatment of cancer
EP4090377A1 (en) 2020-01-13 2022-11-23 Synaffix B.V. Conjugates of antibodies an immune cell engagers
EP4103607A4 (en) * 2020-02-16 2023-12-20 Aulos Bioscience, Inc MODIFIED ANTI-IL-2 ANTIBODIES
AU2021327147A1 (en) * 2020-08-18 2023-04-06 Universität Zürich A CD25-biased anti-IL-2 antibody
CN117157107A (zh) 2021-02-08 2023-12-01 西纳福克斯股份有限公司 多功能抗体
KR20240082411A (ko) 2021-10-14 2024-06-10 라띠콘 (수저우) 바이오파마슈티칼스 코., 엘티디. 신규 항체-사이토카인 융합 단백질, 이의 제조 방법 및 이의 용도
US11773160B1 (en) 2022-08-05 2023-10-03 Anaveon AG Immune-stimulating IL-2 fusion proteins
CN119775409B (zh) * 2025-03-05 2025-07-11 深圳真实生物医药科技有限公司 靶向sost的抗体及其用途

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1340853C (en) * 1983-12-23 1999-12-21 Hsiang-Fu Kung Purification of recombinant interleukin-2
JPS62269698A (ja) * 1986-03-17 1987-11-24 エフ．ホフマン　―　ラ　ロシュ　アーゲー Ｉｌ−２蛋白質に対するモノクロ−ナル抗体
CA2263129C (en) 1996-08-16 2007-01-09 Schering Corporation Mammalian cell surface antigens; related reagents
US6111090A (en) 1996-08-16 2000-08-29 Schering Corporation Mammalian cell surface antigens; related reagents
ATE386802T1 (de) 1997-06-12 2008-03-15 Novartis Int Pharm Ltd Künstliche antikörperpolypeptide
WO2004060319A2 (en) 2002-12-30 2004-07-22 3M Innovative Properties Company Immunostimulatory combinations
EP1765402A2 (en) 2004-06-04 2007-03-28 Duke University Methods and compositions for enhancement of immunity by in vivo depletion of immunosuppressive cell activity
NZ563213A (en) * 2005-06-01 2009-07-31 Micromet Ag Anti-IL2 antibodies
CN102875681A (zh) 2005-07-08 2013-01-16 拜奥根Idec马萨诸塞公司 抗-αvβ6抗体及其用途
JP2009527500A (ja) * 2006-02-16 2009-07-30 ナセント・バイオロジックス・インコーポレイテッド 免疫機能を改善するための方法および哺乳動物対象における疾患の防止または処置のための方法
CN101045923B (zh) * 2006-03-31 2011-11-23 沈阳三生制药有限责任公司 生产一种白细胞介素类似物的方法
BRPI0907718A2 (pt) 2008-02-11 2017-06-13 Curetech Ltd método para tratar um tumor, método para melhorar a tolerabilidade a pelo menos um agente quimiterápico, método para aumentar a sobrevida de um indivíduo que tem um tumor, método para reduzir ou prevenir recidiva tumoral, uso de um anticorpo monoclonal humanizado ou seu fragmento e anticorpo monoclonal humanizado ou seu fragmento
SI3042917T1 (en) 2010-08-12 2018-04-30 Eli Lilly And Company Anti-n3pglu amyloid beta peptide antibodies and uses thereof
HUE040326T2 (hu) 2011-02-10 2019-03-28 Roche Glycart Ag Mutáns interleukon-2 polipeptidek
WO2013157105A1 (ja) 2012-04-18 2013-10-24 公立大学法人大阪市立大学 ムチンサブタイプ５ａｃ特異的ヒト化抗体およびその利用
CN103566377A (zh) 2012-07-18 2014-02-12 上海博笛生物科技有限公司 癌症的靶向免疫治疗
WO2015109212A1 (en) * 2014-01-17 2015-07-23 Pfizer Inc. Anti-il-2 antibodies and compositions and uses thereof

Similar Documents

Publication Publication Date Title
JP2017525343A5 (cg-RX-API-DMAC7.html)
JP2022177090A5 (cg-RX-API-DMAC7.html)
JP2018536393A5 (cg-RX-API-DMAC7.html)
RU2017115315A (ru) Антитела к рецептору глюкокортикоид-индуцированного фактора некроза опухоли (gitr) и способы их применения
JP2020500538A5 (cg-RX-API-DMAC7.html)
NZ713461A (en) Polypeptides and polynucleotides, and uses thereof for treatment of immune related disorders and cancer
AR105026A1 (es) ANTICUERPOS MADURADOS POR AFINIDAD Y HUMANIZADOS PARA FcRH5 Y MÉTODOS PARA SU USO
MY198942A (en) Anti-tau antibodies and methods of use
PE20130817A1 (es) Anticuerpos peptidicos beta amiloide anti-n3pglu y usos de los mismos
JP2017505125A5 (cg-RX-API-DMAC7.html)
JP2019528683A5 (cg-RX-API-DMAC7.html)
RU2014108309A (ru) Антиполиубиквитиновые антитела и способы применения
PE20240802A1 (es) Anticuerpos multiespecificos con especificidad para il-4r e il-31
NZ628943A (en) Human antibodies to clostridium difficile toxins
JP2020537520A5 (cg-RX-API-DMAC7.html)
RU2016107814A (ru) Новое антитело к tslp-рецептору человека
AR103713A1 (es) Anticuerpos contra tau y sus usos
JP2016520595A5 (cg-RX-API-DMAC7.html)
AR104906A1 (es) Anticuerpos dirigidos a la proteína morfogenética ósea 9 (bmp9) y métodos a partir de estos
HRP20192038T1 (hr) Protutijela receptora anti-epidermalnog faktora rasta (egfr)
RU2017134043A (ru) Модифицированные антитела igg, которые связываются с трансформирующим фактором роста бета-1 с высокой аффинностью, авидностью и специфичностью
RU2014145536A (ru) Антитело против adamts-5, его производные и их применение
RU2016143552A (ru) Гуманизированные антитела к антигену Томсена-Фриденрайха
RU2016129166A (ru) Антитела, специфичные к альфа-энолазе, и способы применения в противоопухолевой терапии
JP2017511152A5 (cg-RX-API-DMAC7.html)